Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trial.

Hites, Maya Lapique, Eva Larranaga Massonnaud, Clément R Belhadi, Drifa Jamard, Simon Goehringer, François Danion, François Reignier, Jean de Castro, Nathalie Garot, Denis Lacombe, Karine Tolsma, Violaine Faure, Emmanuel Malvy, Denis Staub, Thérèse Courjon, Johan Cazenave-Roblot, France Dyrhol Riise, Anne Ma Leturnier, Paul Martin-Blondel, Guillaume Roger, Claire Akinosoglou, Karolina Moing, Vincent Le Piroth, Lionel Sellier, Pierre Lescure, Xavier Trøseid, Marius Clevenbergh, Philippe Dalgard, Olav Gallien, Sébastien Gousseff, Marie Loubet, Paul Vardon-Bounes, Fanny Visée, Clotilde Belkhir, Leïla [UCL] Botelho-Nevers, Élisabeth Cabié, André Kotanidou, Anastasia Lanternier, Fanny Rouveix-Nordon, Elisabeth Silva, Susana Thiery, Guillaume Poignard, Pascal Carcelain, Guislaine Diallo, Alpha Mercier, Noémie Terzic, Vida Bouscambert-Duchamp, Maude Gaymard, Alexandre Trabaud, Mary-Anne Destras, Grégory Josset, Laurence Billard, Nicolas Han, Thi-Hong-Lien Guedj, Jérémie Couffin-Cadiergues, Sandrine Dechanet, Aline Delmas, Christelle Esperou, Hélène Fougerou-Leurent, Claire Mestre, Soizic Le Métois, Anabelle Noret, Marion Bally, Isabelle Dergan-Dylon, Sebastián Tubiana, Sarah Kalif, Ouifiya Bergaud, Nathalie Leveau, Benjamin Eustace, Joe Greil, Richard Hajdu, Edit Halanova, Monika Paiva, Jose-Artur Piekarska, Anna Rodriguez Baño, Jesus Tonby, Kristian Trojánek, Milan Tsiodras, Sotirios Unal, Serhat Burdet, Charles Costagliola, Dominique Yazdanpanah, Yazdan Peiffer-Smadja, Nathan Mentré, France Ader, Florence DisCoVeRy study group et al.[show all]

Dear Editor, We read with great interest the recent article by Kamboj et al., in which they described the risk of developing moderate to severe Coronavirus Disease 2019 (COVID-19) in patients with hematological malignancies receiving tixagevimab-cilgavimab (T-C) during a period in which the dominant circulating variants of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) were resistant to T-C.1 The authors highlight the ongoing need to urgently address the mAb treatment gap, particularly for immunocompromised patients. The unmet need is further highlighted by the DisCoVeRy Phase 3, adaptive, multicentre European, randomized, double-blind, superiority trial that evaluated the efficacy and safety of intravenous T-C in SARS-CoV-2 antigenic positive patients (i.e those with a high SARS-CoV-2 viral load) hospitalized with COVID-19 and followed-up to day 90. [...]